This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- Please refer to the local labeling for relevant information regarding TREMFYA and the occurrence of injection site reactions (ISRs).
- In a phase 3b, multicenter, double-blind (DB), randomized clinical trial, ISRs were reported in 2.7% (6/225) of patients receiving TREMFYA and 0.9% (1/113) of patients receiving placebo (PBO) through week 16.1
- An integrated pooled safety analysis evaluated the incidence rates of ISRs from 11 phase 2 and 3 clinical trials in adult patients with moderate to severe plaque psoriasis (PsO) and active psoriatic arthritis (PsA).2
- The median duration of TREMFYA exposure was 1.7 years, 3.5 years, and 1.2 years in the pooled population, PsO group, and PsA group, respectively.
- ISRs occurred in 5.3% (153/2891) and in 2% (30/1508) of patients receiving TREMFYA in the pooled plaque PsO studies and the pooled active PsA studies, respectively.
CLINICAL DATA
Phase 3 Clinical Trial
Gold et al (2026)1 assessed the clinical results from the SPECTREM trial through the end of the PBO-controlled period at week 16.
Study Design/Methods
SPECTREM (NCT06039189) is a multicenter, DB, randomized, phase 3b clinical trial that evaluated the safety and efficacy of TREMFYA compared with PBO in patients with low body surface area (BSA) (2-15%), moderate plaque PsO involving 1 or more high-impact site(s) (scalp, face, genitals, intertriginous areas).
- A total of 338 patients were randomized in a 2:1 ratio to receive subcutaneous (SC) TREMFYA 100 mg (n=225) at weeks 0 and 4 and then every 8 weeks (Q8W) or PBO
(n=113), with PBO crossover to TREMFYA at week 16. - Adverse events (AEs), serious adverse events (SAEs), infections, and ISRs were monitored. Safety terms were coded using MedDRA version 26.1.
Safety Results for ISRs
- In the TREMFYA group through week 16, ISRs were reported in 2.7% (6/225) of patients, with each patient experiencing 1 ISR. Of these events, 4 were mild and 2 were moderate in severity, and none led to treatment discontinuation.
- In the PBO group through week 16, 0.9% (1/113) of patients experienced an ISR.
Pooled Safety Analysis
Strober et al (2024)2 evaluated the safety of TREMFYA in adult patients with psoriatic disease in an integrated pooled analysis of data from 11 randomized (7 plaque PsO; 4 active PsA), phase 2 and 3 studies.
Study Design/Methods
- All plaque PsO studies (X-PLORE, VOYAGE 1, VOYAGE 2, ORION, Japan Registration) included a PBO-controlled period (weeks 0-16), except NAVIGATE (active comparator: ustekinumab) and ECLIPSE (active comparator: secukinumab).
- All active PsA studies (Phase 2, DISCOVER-1, DISCOVER-2, and COSMOS) included a PBO-controlled period (weeks 0-24).
- This long-term safety analysis included a total of 4399 patients (PsO, n=2891; PsA, n=1508) who received ≥1 administration of TREMFYA for a total follow-up of 10,787 patient-years (PYs); see Table: Safety Reporting Period for Clinical Studies Included in the Integrated Analysis.
- The median duration of TREMFYA exposure was 1.7 years, 3.5 years, and 1.2 years in the pooled population, PsO group, and PsA group, respectively.
Safety Reporting Period for Clinical Studies Included in the Integrated Analysis2
|
|
|---|
|
|
|
|
|
|
|---|
Weeks
| 0-264
| 16-60
| 0-40
| 0-56
| 0-156
| 0-52
|
|
|
|---|
|
|
|
|
|---|
Weeks
| 0-60
| 0-112
| 0-56
| 0-56
|
Abbreviations: PsA, psoriatic arthritis; PsO, psoriasis; PY, patient-year. aAll studies included a placebo-controlled period (weeks 0-16), except NAVIGATE and ECLIPSE. bData summarized for safety reporting periods of up to 5 years, including patients randomized to placebo, TREMFYA, or adalimumab (VOYAGE 1 and VOYAGE 2 only) at baseline who crossed over to TREMFYA and patients randomized to TREMFYA after receiving open-label ustekinumab (NAVIGATE). cAll studies included a placebo-controlled period (weeks 0-24). dData summarized for safety reporting periods of up to 2 years, including patients randomized to placebo at baseline who crossed over to TREMFYA at week 24.
|
Safety Results of ISRs
- In the pooled plaque PsO studies, ISRs occurred in 5.3% (153/2891) of patients receiving TREMFYA.
- Of the 57,603 injections, 464 (0.8%) were reported with ISRs and most were described as mild.
- In the pooled active PsA studies, ISRs occurred in 2% (30/1508) of patients receiving TREMFYA.
- Of the 19,303 injections, 75 (0.4%) were reported with ISRs and most were described as mild.
- No events of serum-like sickness or anaphylactic reactions related to TREMFYA were reported.
Literature Search
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 07 September 2026.
| 1 | Gold LS, Gottlieb AB, Armstrong AW, et al. SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. Br J Dermatol. 2026;194:25-36. |
| 2 | Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47(1):39-57. |